Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stem celltherapy for ischemic heart failure.

Doreen Rosenstrauch1, Gregor Poglajen, Nina Zidar

  • 1Heart Failure Research Laboratory, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas 77030, USA. Doreen.Rosenstrauch@uth.tmc.edu

Texas Heart Institute Journal
|January 6, 2006
PubMed
Summary

Stem cell therapy shows promise for managing ischemic heart failure. Research into various cell types aims to regenerate heart muscle, potentially offering a new treatment for this growing condition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

"Histologic type, treatment and prognosis of carcinomas of the larynx: A review".

Virchows Archiv : an international journal of pathology·2026
Same author

Management of Tacrolimus-induced thrombotic microangiopathy in a heart transplant recipient: Utilizing novel immunosuppression strategies.

JHLT open·2026
Same author

Hemodynamic-guided V-A ECMO management for cardiogenic shock: Insight from initial experience from TWEET study (to wean an ECMO trials).

Perfusion·2026
Same author

Left Ventricular Venting Strategies for Cardiogenic Shock in Patients Treated With Extracorporeal Cardiopulmonary Support V-A ECMO: From Left Ventricular Unloading to Offloading.

The American journal of cardiology·2026
Same author

Epigenetic alterations in head and neck cancer: a brief update.

Virchows Archiv : an international journal of pathology·2026
Same author

Belatacept as an Emerging Option in Immunosuppression-Induced Thrombotic Microangiopathy After Heart Transplantation.

JACC. Case reports·2026

Area of Science:

  • Cardiovascular Medicine
  • Regenerative Medicine
  • Stem Cell Biology

Background:

  • Ischemic heart disease prevalence is rising, increasing the need for effective heart failure management.
  • Current treatments for ischemic heart failure have limitations, driving research into novel therapeutic approaches.
  • Stem cell therapy is being explored for its potential to repair or regenerate heart muscle damaged by ischemia.

Purpose of the Study:

  • To review the current landscape of stem cell therapy for ischemic heart failure.
  • To identify various cell types under investigation for myocardial regeneration.
  • To assess the preclinical and early clinical evidence supporting stem cell therapy in this context.

Main Methods:

  • Review of preclinical animal studies on stem cell transplantation for ischemic heart disease.

Related Experiment Videos

  • Analysis of early-phase clinical trial data evaluating different stem cell types.
  • Compilation of data on cell types including embryonic stem cells, cardiac progenitors, and bone marrow-derived cells.

    • Main Results:

    • Multiple stem cell types are being investigated, each with unique properties and potential mechanisms of action.
    • Preclinical studies demonstrate the capacity of stem cells to improve cardiac function and structure in animal models.
    • Early clinical trials indicate promising safety and efficacy signals for stem cell therapy in human heart failure patients.

    Conclusions:

    • Stem cell therapy represents a promising frontier in the management of ischemic heart failure.
    • Continued research and clinical trials are essential to establish the definitive role of stem cells in cardiac repair.
    • This approach may soon become a vital addition to the therapeutic arsenal for heart failure patients.